Vasca Granted Patents for a Unique Peritoneal Dialysis Application Using the LifeSite System and the Use of Alcohol as a Catheter Lock Solution.Business Editors/Health/Medical Writers TEWKSBURY, Mass.--(BUSINESS WIRE)--Sept. 10, 2003 Vasca, Inc., a privately held medical device company, announced today that the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patent Office has issued the Company two additional patents this month in the field of dialysis access. Patent number 6,585,681, entitled Methods and Apparatus for Performing Flow-Through Peritoneal Dialysis peritoneal dialysis n. The removal of soluble substances and water from the body by transfer across the peritoneum, utilizing a solution which is intermittently introduced into and removed from the peritoneal cavity. and patent number 6,592,564, entitled Methods and Kits for Locking and Disinfecting Implanted Catheters were the twenty-fifth and twenty-sixth patents issued to Vasca by the United States Patent Office. These two patents contribute significantly to Vasca's growing intellectual property position. Methods and Apparatus for Performing Flow-Through Peritoneal Dialysis focuses on the use of the LifeSite(R) technology for peritoneal dialysis and discloses an access technology that offers the potential for improved peritoneal dialysis delivery. Specifically, the patent addresses the use of technology Vasca has developed for patients undergoing continuous flow peritoneal dialysis (CFPD CFPD Cubic Feet Per Day CFPD Center Flat Panel Display CFPD Chagrin Falls Police Department ). CFPD is an advanced form of peritoneal dialysis therapy which allows for higher dialysis clearances as a result of the rapid movement of large volumes of solution into and out of the peritoneal cavity peritoneal cavity n. The potential space between the parietal and visceral layers of the peritoneum. peritoneal cavity (per´it . Vasca's proprietary technology allows for this rapid cycling of fluid while only requiring a single access location. Methods and Kits for Locking and Disinfecting Implanted Catheters discloses the use of alcohol as a locking solution in catheters and the LifeSite System. In addition to the benefits of being inexpensive and easily prepared, alcohol has strong antimicrobial properties and may reduce the rate of biofilm Biofilm An adhesive substance, the glycocalyx, and the bacterial community which it envelops at the interface of a liquid and a surface. When a liquid is in contact with an inert surface, any bacteria within the liquid are attracted to the surface and adhere formation when used as a catheter lock. "Vasca continues to strengthen its technology leadership position in the area of subcutaneous dialysis access with the issuance of these patents," stated John Moran, M.D., Vasca's Senior Medical Advisor. "The specific methods and devices described in these patents are the result of Vasca's efforts to develop alternative patient care approaches designed to improve clinical outcomes for peritoneal dialysis and hemodialysis patients." About the LifeSite System: The LifeSite System is a new and innovative technology for patients requiring dialysis access. The LifeSite Hemodialysis Access System is the first totally subcutaneous hemodialysis access system commercially available to patients in the United States. Over 6,000 patients have utilized the LifeSite System for hemodialysis access in the United States since it received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. 510(k) Clearance in August 2000. The LifeSite System provides an immediate access alternative that delivers high flow rates, a low complication rate and ease of use while patients wait for the development of a functioning arteriovenous arteriovenous /ar·te·rio·ve·nous/ (-ve´nus) both arterial and venous; pertaining to or affecting an artery and a vein. ar·te·ri·o·ve·nous adj. Abbr. (AV) fistula fistula (fĭs`ch  lə), abnormal, usually ulcerous channellike formation between two internal organs or between an internal organ and the skin. . The LifeSite Peritoneal Dialysis System has been commercialized in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to theEuropean Community . About the Company: Vasca, Inc., founded in 1996, is focused on becoming the worldwide leader in Body Access Management by developing innovative access technologies that improve the quality of patient care. For more information on Vasca, Inc. and the LifeSite System visit the company website at www.vasca.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion